DLL3 approval in eSCLC and how it can be used in extrapulmonary PDNEC/small cell

NETCast
05/11/2024 37 min Episodio 26
DLL3 approval in eSCLC and how it can be used in extrapulmonary PDNEC/small cell

Listen "DLL3 approval in eSCLC and how it can be used in extrapulmonary PDNEC/small cell"

Descargar episodio

Episode Synopsis


DLL3 approval in eSCLC and how it can be used in extrapulmonary PDNEC/small cell. Dr. Phan speaks with Dr. Jain about treatment options for neuroendocrine carcinoma.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

More episodes of the podcast NETCast

Current State of NETs, Successes, and Future Directions in Latin America 09/09/2025
The Intersection of Compassion and Burnout in NETs 12/08/2025
Promising Advances in NEC Research and Treatment 27/05/2025
Understanding the COMPETE Study and Its Implications 31/03/2025
Terapias para tumores neuroendocrinos en México 25/02/2025
2024 Symposium Abstracts: The Promise of PRRT in Neuroendocrine Tumor Treatment - Recorded November 22nd, 2024 14/01/2025
2024 Symposium Abstracts: New Research Using Biomarkers for Neuroendocrine Tumor Treatment - Recorded November 21st, 2024 07/01/2025
2024 Symposium Abstracts: Innovative Therapies for Neuroendocrine Tumors - Recorded November 20th, 2024 31/12/2024
2024 Symposium: Bridging the Gap with Patient Advocacy Groups - Recorded November 23rd, 2024 11/12/2024
American Joint Committee on Cancer (AJCC) The Future of Neuroendocrine Tumor Management 27/11/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA